Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2023-06-15 00:00:00 ET · period of report 2023-06-13 · accession 0001127602-23-018775 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-15 | 2023-06-14 | BCRX | Hutson Nancy J | Dir | S - Sale | $8.04 | -12.9K | 81.8K | -14% | -$103.4K |
| D | 2023-06-15 | 2023-06-13 | BCRX | Hutson Nancy J | Dir | A - Grant | $0.00 | +16.7K | 94.7K | +21% | $0 |
| D | 2023-06-15 | 2023-06-13 | BCRX | Hutson Nancy J | Dir | A - Grant | $0.00 | +39.1K | 39.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-14 | S | D | 12,866 | $8.04 | 81,818 | D | — | — | (F2) The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $7.89 to $8.12. The reporting person will provide to the issuer, or any security holder of the issuer, or the SEC staff upon request, full information regarding the number of shares purchased at each price within the range set forth in the footnote. |
| 2 | Common | Common Stock | 2023-06-13 | A | A | 16,745 | $0.00 | 94,684 | D | — | — | (F1) Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| 3 | Derivative | Automatic Stock Option Grant | 2023-06-13 | A | A | 39,072 | $0.00 | 39,072 | D | $8.18 · 2024-06-13 to 2033-06-13 | 39,072 Common Stock | (F3) Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |